Spots Global Cancer Trial Database for Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer Patients
Official Title: Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer Patients
Study ID: NCT04708639
Interventions
Study Description
Brief Summary: Circulating tumor DNA can be used to monitor the treatment effect and identify developing resistance mutations during ALK directed TKI treatment.
Detailed Description: The purpose and objectives of the non-interventional study with primary data collection is * To determine if monitoring the amount of translocated DNA in the blood reflects alectinib treatment effect. * To assess the presence and type of resistance mutations using ctDNA at the time patients experience clinical progression on alectinib. * To investigate if the resistance mutations identified at clinical progression could have been identified in blood samples taken before clinically evident progression.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Aarhus University Hospital, Aarhus, , Denmark
Contact Details
Name: Peter Meldgaard, MD, PhD
Affiliation: Aarhus University Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
